Mathew Nguyen
Psychiatry · Gainesville, FLNPI 1083650261
Payments from drug & device makers
Across 523 payments — averaging $211.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$104K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Alkermes, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$849
- AbbVie$474
- plus $744 from 7 others
What the payments were for
- Speaking & faculty fees$76,50069%
- Travel & lodging$20,80319%
- Food & beverage$13,04312%
- Education$870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 300 | $104,002 |
| Otsuka America Pharmaceutical, Inc. | 110 | $1,756 |
| Neurocrine Biosciences, Inc. | 43 | $1,541 |
| Alkermes, Inc. | 32 | $1,067 |
| Teva Pharmaceuticals USA, Inc. | 9 | $849 |
| AbbVie(2 entities) | 5 | $474 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $455 |
| Supernus Pharmaceuticals, Inc. | 2 | $106 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $40 |
| Indivior Inc. | 2 | $28 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$98,001
- INVEGA TRINZA$96,680
- ARISTADA$864
- INGREZZA$712
- Austedo XR$465
- VRAYLAR$456
- LYBALVI$407
- CAPLYTA$226
- AUSTEDO$225
- ARISTADA INITIO$216
- INVEGA$123
- ABILIFY MAINTENA$117
- UZEDY$116
- SPRAVATO$112
How this compares
$110,433 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 87 | $267,829 |
| Invega HafyeraPaliperidone Palmitate | 12 | $259,356 |
| IngrezzaValbenazine Tosylate | 15 | $137,668 |
| Abilify MaintenaAripiprazole | 11 | $33,192 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $104,002 | $267,82987 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,541 | $137,66815 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,756 | $33,19211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Gainesville
- Lawrence ReccoppaGainesville$968K
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.